PLD-106
Renal cell carcinoma & hepatocellular carcinoma
PreclinicalActive
Key Facts
About PeLeMed
AI‑powered biotech delivering next‑gen FLT3 inhibitors and anti‑HBV agents for unmet oncology and viral disease needs.
View full company profileRenal cell carcinoma & hepatocellular carcinoma
AI‑powered biotech delivering next‑gen FLT3 inhibitors and anti‑HBV agents for unmet oncology and viral disease needs.
View full company profile